| ACPA | Anti-citrullinated protein antibody |
| ACR | American College of Rheumatology |
| ACR20 | American College of Rheumatology 20% improvement criteria |
| ACR50 | American College of Rheumatology 50% improvement criteria |
| ACR70 | American College of Rheumatology 70% improvement criteria |
| Akt | Protein kinase B |
| anti-CCP | Anti-cyclic citrullinated peptide antibody |
| AP-1 | Activator protein 1 |
| APC | Antigen-presenting cell |
| bDMARD | Biologic disease-modifying antirheumatic drug |
| BCL2 | B-cell lymphoma 2 |
| BCL-XL | B-cell lymphoma-extra large |
| C3a | Complement component 3a |
| C5a | Complement component 5a |
| CCL17 | Chemokine (C-C motif) ligand 17 |
| CCL2 | Chemokine (C-C motif) ligand 2 |
| CCL22 | Chemokine (C-C motif) ligand 22 |
| CCL3 | Chemokine (C-C motif) ligand 3 |
| CCL5 | C-C motif chemokine ligand 5 |
| CCR2 | C-C chemokine receptor type 2 |
| CD4 | Cluster of differentiation 4 |
| CD40 | Cluster of differentiation 40 |
| CD80 | Cluster of differentiation 80 |
| CD86 | Cluster of differentiation 86 |
| CDAI | Clinical disease activity index |
| c-Fos | Cellular FOS proto-oncogene |
| CHD | Cytokine receptor homology domain |
| CIA | Collagen-induced arthritis |
| CRP | C-reactive protein |
| CTLA4 | Cytotoxic T-lymphocyte antigen 4 |
| CXCL10 | C-X-C motif chemokine ligand 10 |
| CXCL8 | Chemokine (C-X-C motif) ligand 8 |
| CX3CR1 | CX3C chemokine receptor 1 |
| DAS28 | Disease activity score in 28 joints |
| DAS28-CRP | Disease activity score in 28 joints with C-reactive protein |
| DCE-MRI | Dynamic contrast-enhanced MRI |
| DMARD | Disease-modifying antirheumatic drug |
| Elk-1 | ETS-like protein 1 |
| ERK1/2 | Extracellular signal-regulated kinase 1/2 |
| ESR | Erythrocyte sedimentation rate |
| EULAR | European League Against Rheumatism |
| FLS | Fibroblast-like synoviocyte |
| GLS | Glutaminase |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| GM-CSFR | Granulocyte-macrophage colony-stimulating factor receptor |
| GM-CSFRα | Granulocyte-macrophage colony-stimulating factor receptor alpha subunit |
| GM-CSFRβc | Granulocyte-macrophage colony-stimulating factor receptor β common subunit |
| GM-DM | GM-CSF-differentiated macrophage |
| HAQ-DI | Health assessment questionnaire disability index |
| HK | Hexokinase 2 |
| HLA-DRB1 | Human leukocyte antigen-DR beta 1 |
| IFN-γ | Interferon gamma |
| IgG1 | Immunoglobulin G1 |
| IKK | IκB Kinase |
| IL-12 | Interleukin 12 |
| IL-17 | Interleukin 17 |
| IL-17A | Interleukin 17A |
| IL-17F | Interleukin 17F |
| IL-1β | Interleukin 1 beta |
| IL-22 | Interleukin 22 |
| IL-23 | Interleukin 23 |
| IL-3 | Interleukin 3 |
| IL-5 | Interleukin 5 |
| IL-6 | Interleukin 6 |
| IL-8 | Interleukin 8 |
| iNOS | Inducible nitric oxide synthase |
| IRF4 | Interferon regulatory factor 4 |
| IRF5 | Interferon regulatory factor 5 |
| IκBα | Inhibitor of kappa B alpha |
| i.v. | Intravenous injection |
| JAK2 | Janus kinase |
| JAK2 | Janus kinase 2 |
| JIA | Juvenile idiopathic arthritis |
| Ly-6Chigh | Lymphocyte antigen 6C high-expressing monocytes |
| M1 | Classically activated macrophage phenotype |
| mAb | Monoclonal antibody |
| MAPK | Mitogen-activated protein kinase |
| MAPK/ERK | Mitogen-activated protein kinase/extracellular signal-regulated kinase |
| MCL1 | Myeloid cell leukemia 1 |
| M-CSF | Macrophage colony-stimulating factor |
| MEK1/2 | Mitogen-activated protein kinase kinase 1/2 |
| MHC | Major histocompatibility complex |
| MHC-II | Major histocompatibility complex type II |
| MMP | Matrix metalloproteinase |
| MMP-1 | Matrix metalloproteinase 1 |
| MMP-13 | Matrix metalloproteinase 13 |
| MMP-3 | Matrix metalloproteinase 3 |
| MMP-9 | Matrix metalloproteinase 9 |
| MRI | Magnetic resonance imaging |
| mRNA | Messenger ribonucleic acid |
| mTOR | Mechanistic target of rapamycin |
| mTORC2 | Mechanistic target of rapamycin complex 2 |
| NET | Neutrophil extracellular trap |
| NFATc1 | Nuclear factor of activated T-cells, cytoplasmic 1 |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NO | Nitric oxide |
| OMERACT | Outcome measures in rheumatology clinical trials |
| PDK1 | Phosphoinositide-dependent kinase 1 |
| PET | Positron emission tomography |
| PFK1 | Phosphofructokinase 1 |
| PI3K | Phosphoinositide 3-kinase |
| PI3K/Akt | Phosphoinositide 3-kinase/protein kinase B |
| PIP2 | Phosphatidylinositol 4,5-bisphosphate |
| PIP3 | Phosphatidylinositol 3,4,5-trisphosphate |
| PK | Pharmacokinetics |
| PTPN22 | Protein tyrosine phosphatase non-receptor type 22 |
| RA | Rheumatoid arthritis |
| RA-ILD | Rheumatoid arthritis-associated interstitial lung disease |
| Raf-1 | Rapidly accelerated fibrosarcoma 1 |
| RAMRIS | Rheumatoid arthritis magnetic resonance imaging score |
| RAMRIQ | Rheumatoid arthritis magnetic resonance imaging quantitative |
| RANK | Receptor activator of nuclear factor κB |
| RANKL | Receptor activator of nuclear factor κB ligand |
| Ras | Rat sarcoma |
| RF | Rheumatoid factor |
| ROS | Reactive oxygen species |
| s.c. | Subcutaneous injection |
| SH2 | Src homology 2 |
| sJIA | Systemic juvenile idiopathic arthritis |
| SOCS3 | Suppressor of cytokine signaling 3 |
| STAT | Signal transducer and activator of transcription |
| STAT4 | Signal transducer and activator of transcription 4 |
| STAT5 | Signal transducer and activator of transcription 5 |
| Th | T helper lymphocyte |
| Th1 | T helper 1 cell |
| Th17 | T helper 17 cell |
| TNF-α | Tumor necrosis factor alpha |
| Treg | Regulatory T cell |